Lord, Abbett & Co. LLC Uni Qure N.V. Transaction History

Lord, Abbett & Co. LLC

$30.6 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 07, 2024	BUY	$18.7 - $23.07 $1.95 Million - $2.4 Million	104,162 Added 67.46%	258,571 $5.21 Million
Q1 2023 May 12, 2023	BUY	$18.7 - $23.07 $1.95 Million - $2.4 Million	104,162 Added 67.46%	258,571 $5.21 Million
Q4 2022 Oct 07, 2024	BUY	$18.12 - $27.32 $2.8 Million - $4.22 Million	154,409 New	154,409 $3.5 Million
Q4 2022 Feb 10, 2023	BUY	$18.12 - $27.32 $2.8 Million - $4.22 Million	154,409 New	154,409 $3.5 Million
Q2 2021 Aug 11, 2021	SELL	$29.97 - $37.17 $1.25 Million - $1.56 Million	-41,871 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $1.74 Million - $2.31 Million	-48,383 Reduced 53.61%	41,871 $1.54 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $10.3 Million - $15.5 Million	-228,579 Reduced 71.69%	90,254 $4.07 Million
Q1 2020 May 14, 2020	SELL	$40.01 - $73.97 $3.76 Million - $6.95 Million	-93,982 Reduced 22.77%	318,833 $15.1 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $225,304 - $452,794	6,068 Added 1.49%	412,815 $29.6 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $6.99 Million - $13.6 Million	-177,582 Reduced 30.39%	406,747 $16 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $3.34 Million - $5.2 Million	-63,297 Reduced 9.77%	584,329 $45.7 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $13.6 Million - $34 Million	496,355 Added 328.12%	647,626 $38.6 Million
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $83,949 - $124,930	3,682 Added 2.49%	151,271 $4.36 Million
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $4.39 Million - $6.36 Million	147,589 New	147,589 $5.37 Million

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account